• Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape.
• CS5001 is also being investigated globally in a multi-center Phase Ib clinical trial for multiple solid tumor types.

SUZHOU, China, March 6, 2025 /PRNewswire/ — CStone Pharmaceuticals (“CStone”, HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Phase Ib clinical trial application in Australia for CS5001, its ROR1-targeting antibody-drug conjugate (ADC), in combination with first-line standard-of-care (SoC) for DLBCL. CS5001 is also being evaluated as both a monotherapy and in combination with a PD-L1 inhibitor for advanced solid tumors in an ongoing global multi-center clinical trial.

Building on promising data from CS5001 monotherapy in later-line aggressive and indolent lymphomas, this Phase Ib trial aims to expand the therapeutic potential of CS5001 across all DLBCL stages and solid tumors. The study will explore:

• CS5001 + R-CHOP: First-line treatment for DLBCL patients who have not received prior systemic therapy.
• CS5001 + SoC: For patients with relapsed or refractory DLBCL.
• CS5001 Monotherapy: Targeting ROR1-expressing solid tumors.
• CS5001 + Sugemalimab: Combination therapy for advanced solid tumors.

Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, stated: “We are thrilled to reach another key clinical milestone for CS5001. The existing data underscore its broad potential in both lymphomas and solid tumors. Notably, a ROR1 ADC combined with R-CHP has demonstrated an impressive complete response (CR) rate in a Phase II trial for first-line DLBCL. As we advance from late-line monotherapy to frontline combination therapy, we are optimistic that CS5001 will provide significant clinical benefits to DLBCL patients and establish itself as a first-line treatment option. Meanwhile, we continue to explore CS5001’s potential in solid tumors and eagerly anticipate further positive outcomes.”

The global multi-center Phase Ib trial for CS5001 is actively enrolling patients across the United States, Australia, and China. Recruitment is ongoing for monotherapy cohorts targeting aggressive and indolent advanced lymphomas, which could potentially expand into a Phase II single-arm registrational study. Additional cohorts, including the first-line DLBCL combination therapy and solid tumor monotherapy and combination therapy arms, will be initiated soon.

About CS5001 (ROR1 ADC)

CS5001 is a clinical-stage antibody-drug conjugate (“ADC”) targeting ROR1 (receptor tyrosine kinase-like orphan receptor 1). CS5001 has been uniquely designed with proprietary tumor-cleavable linker and pyrrolobenzodiazepine (“PBD”) prodrug. Only after reaching the tumor, the linker and prodrug are cleaved to release the PBD toxin, resulting in lethal DNA cross-links in cancer cells. The use of the linker plus PBD prodrug effectively helps address the toxicity associated with traditional PBD payloads, leading to a better safety profile. CS5001 has demonstrated complete tumor suppression in several preclinical cancer models and demonstrated favorable serum half-life and pharmacokinetic characteristics. CS5001 is a promising candidate drug with precision treatment potential in both hematologic tumors and malignant solid tumors. Additionally, CS5001 utilizes site-specific conjugation for a precise drug antibody ratio of which enables homogeneous production and large-scale manufacturing.

In October 2020, CStone signed a licensing agreement with LigaChem Biosciences, Inc. (LCB) for the development and commercialization of CS5001 which was originally generated by collaboration of LCB and ABL Bio, both South Korea-based leading biotech companies. Under the agreement, CStone obtains the exclusive global right to develop and commercialize CS5001 outside the Republic of Korea.

The first-in-human data for CS5001 in patients with advanced solid tumors and lymphomas was presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Additionally, the latest clinical data on CS5001 as a monotherapy in patients with advanced lymphomas has recently been presented at the 66th American Society of Hematology (ASH) Annual Meeting.

CS5001 has demonstrated encouraging safety and robust anti-tumor activity in the Phase 1a dose escalation trials across 10 dose levels.

• At the tentative recommended Phase 2 dose (RP2D) of DL8 (125 μg/kg), CS5001 achieved objective response rates (ORRs) of 70% in advanced B-cell lymphoma and 100% in Hodgkin lymphoma.
• Encouraging efficacy signals were also observed in advanced solid tumors, including non-small cell lung cancer and pancreatic cancer.
• CS5001 was well tolerated in heavily pre-treated patients with advanced B-cell lymphomas and solid tumors.

About CStone

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 16 new drug applications (NDAs) covering 9 indications. The company’s pipeline is balanced by 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization. For more information about CStone, please visit www.cstonepharma.com.

Forward-looking statements

The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.

Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes.

BEIJING, March 6, 2025 /PRNewswire/ — Baidu, Inc. (NASDAQ: BIDU and HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)), (“Baidu” or the “Company”), a leading AI company with strong Internet foundation, today announced the pricing of its offering of CNY10 billion aggregate principal amount of CNY-denominated senior unsecured notes (the “Notes”). The Notes were offered in offshore transactions outside the United States to certain non-U.S. persons (the “Notes Offering”) in reliance on Regulation S under the United States Securities Act of 1933, as amended (the “Securities Act”). 

The Notes Offering consists of CNY7.5 billion of 2.70% notes due 2030 and CNY2.5 billion of 3.00% notes due 2035. The Company expects to close the Notes Offering on or about March 12, 2025, subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds from the Notes Offering for general corporate purposes, including repayment of certain existing indebtedness, payment of interest and general corporate purposes.

The Notes have not been and will not be registered under the Securities Act or any state securities laws. They may not be offered or sold in the United States or to, or for the account or benefits of, U.S. persons (as defined in Regulation S under the Securities Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.

The Notes are expected to be listed on The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”).

This announcement shall not constitute an offer to sell or a solicitation of an offer to purchase any securities, in the United States or elsewhere, and shall not constitute an offer, solicitation or sale of the securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. Any offering of securities will be made by means of one or more offering documents, which will contain detailed material information about the Company and its operational and financial performance.

This announcement contains information about the pending Notes Offering, and there can be no assurance that the Notes Offering will be completed.

About Baidu

Founded in 2000, Baidu’s mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong Internet foundation, trading on Nasdaq under “BIDU” and HKEX under “9888”. One Baidu ADS represents eight Class A ordinary shares.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Baidu may also make written or oral forward-looking statements in its periodic reports to the SEC, in announcements made on the website of the Hong Kong Stock Exchange, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Baidu’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Baidu’s growth strategies; its future business development, including development of new products and services; its ability to attract and retain users and customers; competition in the Chinese Internet search and newsfeed market; competition for online marketing customers; changes in the Company’s revenues and certain cost or expense items as a percentage of its revenues; the outcome of ongoing, or any future, litigation or arbitration, including those relating to intellectual property rights; the expected growth of the Chinese-language Internet search and newsfeed market and the number of Internet and broadband users in China; Chinese governmental policies relating to the Internet and Internet search providers, and general economic conditions in China and elsewhere. Further information regarding these and other risks is included in the Company’s annual report on Form 20-F and other documents filed with the SEC, and announcements on the website of the Hong Kong Stock Exchange. Baidu does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this announcement is as of the date of the announcement, and Baidu undertakes no duty to update such information, except as required under applicable law.

KUALA LUMPUR, Malaysia, March 6, 2025 /PRNewswire/ — FinTags Sdn Bhd, Malaysia’s leading XBRL services provider, has introduced specialized XBRL solutions tailored for accounting firms navigating MBRS 2.0. These solutions streamline compliance, enhance accuracy, and improve efficiency, enabling firms to manage multiple client filings with ease.

With the expansion of SSM’s mandatory XBRL reporting, accounting firms face a surge in filings. FinTags’ platform allows firms to scale their digital reporting services without compromising compliance or increasing staff hours.

“Accounting firms are at the frontline of MBRS 2.0, managing complex client submissions under strict deadlines,” said Shobika, Senior Manager of Customer Success at FinTags. “Our solutions transform this challenge into an opportunity by significantly reducing preparation time and rejection rates.”

 Key Features of FinTags’ XBRL Solutions

• Multi-Client Management Platform: A secure online Client Portal offers centralized control, role-based access, automated deadline tracking, and client-specific taxonomy mapping.
• XBRL Libraries: Over 250 pre-validated, industry-specific templates compatible with MFRS and MPERS taxonomies, reducing tagging time by up to 65%.
• White-Label Client Portal: Firms can offer branded XBRL services through customizable interfaces, enhancing their digital reporting capabilities.
• Bulk Discounting Structure: Volume-based pricing increases profitability as service demand grows.

Proven Results for Accounting Firms

“Before FinTags, each XBRL filing required 15-20 hours and multiple reviews,” said Lee Wei Tan, Managing Partner at a Kuala Lumpur accounting firm. “Now, we complete filings in 4-6 hours with zero rejections, turning compliance into a high-margin service.”

Accounting firms using FinTags report:

• 72% reduction in preparation time per filing
• 98.9% first-time acceptance with SSM submissions
• Expanded services to newly regulated sectors under MBRS 2.0

 FinTags XBRL Implementation Program for Accounting Firms

FinTags offers a specialized onboarding program, including:

• Access to the secure online Client Portal
• Workflow integration with existing accounting systems
• Initial client portfolio setup and template creation
• Dedicated account management and regulatory updates

“Accounting firms shouldn’t have to choose between scaling their XBRL practice and maintaining quality,” said Santhosh Wilson, Director – Service Delivery. “Our solutions ensure they achieve both.”

About FinTags

Founded in 2019, FinTags Sdn Bhd specializes in XBRL implementation, digital financial reporting, and regulatory compliance. Recognized by SSM BizTrust, FinTags partners with leading accounting firms across Malaysia and Singapore to drive digital transformation in financial reporting.

Media Contact:
Getsy Jenita
Email: marcom@fintags.com
Tel: +60 3-33101800
https://www.fintags.my

ITASCA, Ill., March 6, 2025 /PRNewswire/ — Lakeside Holding Limited (“Lakeside” or the “Company”) (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market operating through two specialized subsidiaries—American Bear Logistics and Hupan Pharmaceutical (Hubei) Co., Ltd., today announced that it has entered into a securities purchase agreement with an institutional investor for the sale of senior secured 7% original issue discount convertible promissory notes ( “Notes”) in the principal amount of up to $4.5 million, with 40% warrant coverage, to be drawn in tranches, for gross proceeds of up to approximately $4.2 million.  

The Company plans to use the net proceeds when received from the offering for working capital purposes. On March 5, 2025, the initial closing of the first tranche occurred pursuant to which the Company sold a Note in the principal amount of $1,000,000 and warrants to 318,827 shares at an exercise price of $1.9098, for total gross proceeds, before deducting offerings fees and expenses, of $930,000. 

About Lakeside Holding Limited 

Lakeside Holding Limited is a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market. Through two specialized subsidiaries—American Bear Logistics and Hupan Pharmaceutical (Hubei) Co., Ltd.—Lakeside delivers tailored logistics solutions spanning general and specialized sectors.  

American Bear Logistics, with strategic hubs in Chicago, Dallas, Los Angeles, and New York, offers customized cross-border ocean and airfreight solutions, connecting Asia-based logistics service companies and e-commerce platforms with the U.S. market.  

Lakeside recently acquired Hupan Pharmaceutical (Hubei) Co., Ltd., expanding its service scope and enhancing its pharmaceutical logistics and distribution capabilities within China. This strategic move underscores Lakeside’s commitment to advancing integrated cross-border logistics solutions. 

For more information, please visit https://lakeside-holding.com. The Company routinely updates important information on its website. 

Safe Harbor Statement 

This press release contains forward-looking statements that reflect our current expectations and views of future events. Known and unknown risks, uncertainties and other factors, including those listed under “Risk Factors,” may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. You can identify some of these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements involve various risks and uncertainties. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. We qualify all of our forward-looking statements by these cautionary statements. 

Investor Relations Contact:   

Matthew Abenante, IRC
President
Strategic Investor Relations, LLC
Tel: 347-947-2093
Email: matthew@strategic-ir.com